SunTrust Downgrades NewLink Genetics (NLNK) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall St on track for subdued September start as high yields, oil prices dent sentiment
- Oil up more than 2% as renewed US-Iran strikes stoke supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- The Warsh pivot markets didn't expect
- Oil settles up by more than 2.5% as US and Iran resume military attacks
NewLink Genetics Announces Results from Phase 3 IMPRESS Trial of Algenpantucel-L for Patients with Resected Pancreatic Cancer
May 9, 2016 4:01 PM EDTManagement to Host Conference Call
Tuesday, May 10th at 8:30 a.m. ET
AMES, Iowa, May 09, 2016 (GLOBE NEWSWIRE) -- Â NewLink Genetics Corporation (NASDAQ: NLNK) announced today results of its Phase 3 clinical trial for algenpantucel-L for patients with resected pancreatic cancer.Â
The IMPRESS Phase 3 study of algenpantucel-L for patients with resected pancreatic cancer did... More
